BRPI0517457A - métodos para reenovelamento de anticorpos recombinantes - Google Patents

métodos para reenovelamento de anticorpos recombinantes

Info

Publication number
BRPI0517457A
BRPI0517457A BRPI0517457-0A BRPI0517457A BRPI0517457A BR PI0517457 A BRPI0517457 A BR PI0517457A BR PI0517457 A BRPI0517457 A BR PI0517457A BR PI0517457 A BRPI0517457 A BR PI0517457A
Authority
BR
Brazil
Prior art keywords
methods
recombinant antibodies
refolding recombinant
proteins
recombinant
Prior art date
Application number
BRPI0517457-0A
Other languages
English (en)
Inventor
Thomas Dillon
Douglas Rehder
Pavel Bondarenko
Margaret Ricci
Himanshu S Gadgil
Douglas Banks
Joe Zhou
Yuefeng Lu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517457(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0517457A publication Critical patent/BRPI0517457A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A61K39/39525—Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MéTODOS PARA REENOVELAMENTO DE ANTICORPOS RECOMBINANTES. A presente invenção direciona-se geralmente a métodos para produzir um aumento no enriquecimento ou recuperação de formas preferidas de proteínas de IgG. Mais particularmente, a invenção se relaciona a submeter preparações das citadas proteínas de I~G recombinantes com um reagente de acoplamento de redução/oxidação e opcionalmente um agente caotrópico.
BRPI0517457-0A 2004-10-22 2005-10-21 métodos para reenovelamento de anticorpos recombinantes BRPI0517457A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62129504P 2004-10-22 2004-10-22
US70176205P 2005-07-22 2005-07-22
PCT/US2005/038045 WO2006047340A2 (en) 2004-10-22 2005-10-21 Methods for refolding of recombinant antibodies

Publications (1)

Publication Number Publication Date
BRPI0517457A true BRPI0517457A (pt) 2008-10-07

Family

ID=36129791

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517457-0A BRPI0517457A (pt) 2004-10-22 2005-10-21 métodos para reenovelamento de anticorpos recombinantes

Country Status (16)

Country Link
US (1) US7928205B2 (pt)
EP (1) EP1805320B1 (pt)
JP (2) JP5553963B2 (pt)
KR (1) KR101370253B1 (pt)
AU (1) AU2005299716B2 (pt)
BR (1) BRPI0517457A (pt)
CA (1) CA2584211C (pt)
EA (1) EA012162B1 (pt)
IL (1) IL182626A0 (pt)
MA (1) MA29027B1 (pt)
MX (1) MX2007004437A (pt)
NO (1) NO20072571L (pt)
NZ (1) NZ554520A (pt)
RU (1) RU2007118954A (pt)
SG (1) SG156672A1 (pt)
WO (1) WO2006047340A2 (pt)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928205B2 (en) * 2004-10-22 2011-04-19 Amgen Inc. Methods for refolding of recombinant antibodies
EP3623473A1 (en) * 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US7476852B2 (en) * 2005-05-17 2009-01-13 Honeywell International Inc. Ionization-based detection
CA2607663C (en) * 2005-05-19 2014-08-12 Amgen Inc. Compositions and methods for increasing the stability of antibodies
JP5624276B2 (ja) * 2006-03-31 2014-11-12 中外製薬株式会社 抗体の血中動態を制御する方法
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
AU2007307107B2 (en) * 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
WO2008077889A1 (en) * 2006-12-22 2008-07-03 Ares Trading S.A. Analytical method for analyzing c-terminus truncation
ES2667863T3 (es) * 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
KR20190140090A (ko) 2007-07-09 2019-12-18 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
EP2197911A2 (en) * 2007-09-14 2010-06-23 Amgen Inc. Homogeneous antibody populations
ES2566957T3 (es) * 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
AU2016202036B2 (en) * 2007-09-26 2017-12-07 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
EP2236604B1 (en) * 2007-12-05 2016-07-06 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
AU2009222998B2 (en) * 2008-03-12 2013-05-23 Imclone Llc Anti-TYRP1 antibodies
TWI564021B (zh) 2008-04-11 2017-01-01 Chugai Pharmaceutical Co Ltd Repeated binding of antigen to antigen binding molecules
US9029508B2 (en) * 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
PE20100092A1 (es) * 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
PE20100054A1 (es) * 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
RU2011104348A (ru) * 2008-07-08 2012-08-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
BRPI0917298B8 (pt) * 2008-08-19 2021-05-25 Glytech Inc método de produção de glicoproteína e método de rastreamento de glicoproteína
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) * 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
PT2424889E (pt) * 2009-04-30 2015-11-12 Ablynx Nv Método de produção de anticorpos de domínio
MX2011011670A (es) * 2009-05-01 2011-11-18 Abbott Lab Inmunoglobulinas de dominio variable dual y usos de las mismas.
MX2011012136A (es) 2009-05-15 2012-04-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl.
WO2011005488A1 (en) 2009-06-22 2011-01-13 Amgen Inc. Refolding proteins using a chemically controlled redox state
JP2012531428A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
US9005926B2 (en) * 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
AR078651A1 (es) * 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) * 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
MY160445A (en) 2010-08-03 2017-03-15 Abbvie Inc Dual Variable Domain Immunoglobulins And Uses Thereof
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
PL2702164T3 (pl) * 2011-04-29 2016-06-30 Biocon Res Limited Sposób obniżania heterogeniczności przeciwciał i sposób ich wytwarzania
EP3388443A1 (en) 2011-05-13 2018-10-17 Biogen MA Inc. Methods of preventing and removing trisulfide bonds
EP2771364B1 (en) 2011-10-27 2019-05-22 Genmab A/S Production of heterodimeric proteins
EP2788097A4 (en) * 2011-12-07 2015-09-09 Amgen Inc IGG2 DISULFIDE ISOFORMATION SEPARATION
EP2797955A2 (en) 2011-12-30 2014-11-05 AbbVie Inc. Dual variable domain immunoglobulins against il-13 and/or il-17
JP6297029B2 (ja) * 2012-05-31 2018-03-20 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ 多様な官能基を有する粒子による免疫グロブリンｇ調製物のクロマトグラフィー精製
KR20210111353A (ko) 2012-11-01 2021-09-10 애브비 인코포레이티드 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도
RU2768003C2 (ru) 2013-03-08 2022-03-22 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
US20160053028A1 (en) * 2013-03-29 2016-02-25 Daiso Co., Ltd. Medium additive for cell culture
WO2015018421A1 (en) * 2013-08-07 2015-02-12 Rigshospitalet Copenhagen University Hospital Antibodies, compounds and derivatives thereof for use in the treatment of male infertility
KR102332302B1 (ko) * 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
CA3184564A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Methods and compositions comprising an anti-il13 antibody and residual hamster phospholipase b-like 2
DK3050896T3 (da) 2013-09-27 2021-07-19 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af en polypeptid-heteromultimer
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
EP3126389A1 (en) 2014-04-02 2017-02-08 F. Hoffmann-La Roche AG Method for detecting multispecific antibody light chain mispairing
US10647777B2 (en) * 2014-05-28 2020-05-12 Genzyme Corporation Methods of controlling the formation of disulfide bonds in protein solutions
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
DK3221346T3 (da) 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016097300A1 (en) 2014-12-19 2016-06-23 Genmab A/S Rodent bispecific heterodimeric proteins
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
BR112017013398B1 (pt) * 2014-12-22 2023-12-05 Ucb Biopharma Sprl Método de fabricar anticorpo ou fragmento de ligação ao antígeno do mesmo
KR101892883B1 (ko) 2015-02-27 2018-10-05 추가이 세이야쿠 가부시키가이샤 Il-6 관련 질환 치료용 조성물
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
GB201506870D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
JP7092744B2 (ja) * 2016-07-22 2022-06-28 アムジエン・インコーポレーテツド Ｆｃ含有タンパク質を精製する方法
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
BR112020003498A2 (pt) * 2017-08-22 2020-08-25 Biogen Ma, Inc. composições farmacêuticas e regimes de dosagem que contêm anticorpos anti-alfa(v)beta(6)
TW201923069A (zh) 2017-10-02 2019-06-16 美商拜耳保健有限責任公司 以亞硒酸鹽防止細胞培養收獲物中雙硫鍵還原之方法
CA3078157A1 (en) 2017-10-20 2019-04-25 F.Hoffmann-La Roche Ag Method for generating multispecific antibodies from monospecific antibodies
CN111372947A (zh) 2017-10-30 2020-07-03 豪夫迈·罗氏有限公司 在体内从单特异性抗体产生多特异性抗体的方法
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子
US11447547B1 (en) 2017-12-13 2022-09-20 Amgen Inc. Method of antigen-binding protein production
EP3765494A4 (en) 2018-03-15 2022-03-23 Chugai Seiyaku Kabushiki Kaisha ANTI-DENGUE VIRUS ANTIBODIES WITH CROSS-REACTIVITY AGAINST ZIKA VIRUS AND METHODS OF USE
JP2021519790A (ja) 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
JP2021534151A (ja) * 2018-08-15 2021-12-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 下流クロマトグラフィーにおける再酸化によるタンパク質断片化制御戦略
JP2021536353A (ja) 2018-08-31 2021-12-27 ジェンザイム・コーポレーション 無菌クロマトグラフィー樹脂および製造方法におけるその使用
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
CA3173519A1 (en) * 2020-03-31 2021-10-07 Vishnu Priyanka Reddy CHICHILI Method for producing multispecific antigen-binding molecules
CN115397866A (zh) 2020-03-31 2022-11-25 中外制药株式会社 靶向dll3的多特异性抗原结合分子及其用途
JP2023541191A (ja) * 2020-09-14 2023-09-28 ケーラム バイオサイエンシーズ， インコーポレイテッド アミロイドーシスを治療する方法
KR20240055101A (ko) * 2021-09-14 2024-04-26 시일럼 바이오사이언시즈, 인크. 다발성 골수종의 치료 방법

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4766205A (en) 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0293785A3 (en) 1987-05-29 1990-05-02 Oncogen Limited Partnership Cloning and expression of simian transforming growth factor-ss1
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5242687A (en) 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5272071A (en) 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5266317A (en) 1990-10-04 1993-11-30 University Of Georgia Research Foundation, Inc. Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions
DE4113750A1 (de) 1991-04-26 1992-10-29 Boehringer Mannheim Gmbh Verbesserung der renaturierung bei der sekretion von disulfidverbrueckten proteinen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5243041A (en) 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
DE69233051T2 (de) 1991-10-25 2004-03-11 Immunex Corp., Seattle Antikörper gegen CD40-L
AU648214B2 (en) 1991-12-31 1994-04-14 Lucky Limited Recombinant gene coding for human alpha interferon and expression vector thereof, etc.
IL109149A0 (en) 1993-04-01 1994-06-24 Schering Corp In vitro refolding of recombinant fv fragments
WO1995032216A1 (en) 1994-05-25 1995-11-30 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
WO1996000081A1 (en) 1994-06-24 1996-01-04 Immunex Corporation Controlled release polypeptide compositions and methods of treating inflammatory bowel disease
CA2195665A1 (en) 1994-07-22 1996-02-08 Robert Frederick Geoffrey Booth Pharmaceutical compositions comprising a chimaeric tnf binding protein
WO1996040918A2 (en) 1995-06-07 1996-12-19 Immunex Corporation Novel cd40l mutein
US6063905A (en) * 1997-01-07 2000-05-16 Board Of Regents, The University Of Texas System Recombinant human IGA-J. chain dimer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
FR2803303B1 (fr) 2000-01-04 2002-05-10 Aventis Pasteur Glycoproteine d'enveloppe du vih modifiee chimiquement
AUPQ599700A0 (en) 2000-03-03 2000-03-23 Super Internet Site System Pty Ltd On-line geographical directory
AU2002256971B2 (en) 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
CA2438094C (en) * 2001-02-23 2011-10-11 Immunex Corporation Increased recovery of active proteins
NZ530700A (en) 2001-06-21 2009-02-28 Altus Pharmaceuticals Inc Spherical protein particles and methods of making and using them
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
SI1425389T1 (sl) 2001-08-23 2012-02-29 Genmab As Humana protitelesa, specifična za interlevkin 15 (IL-15)
US9557325B2 (en) 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
AU2004248155B2 (en) 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
US7329353B2 (en) 2004-01-23 2008-02-12 Amgen Inc. LC/MS method of analyzing high molecular weight proteins
US7928205B2 (en) * 2004-10-22 2011-04-19 Amgen Inc. Methods for refolding of recombinant antibodies
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta

Also Published As

Publication number Publication date
EP1805320A4 (en) 2009-09-16
CA2584211A1 (en) 2006-05-04
NO20072571L (no) 2007-07-20
WO2006047340A3 (en) 2007-07-05
NZ554520A (en) 2010-03-26
AU2005299716B2 (en) 2012-09-06
CA2584211C (en) 2014-07-08
AU2005299716A1 (en) 2006-05-04
KR20070084483A (ko) 2007-08-24
US20060194280A1 (en) 2006-08-31
KR101370253B1 (ko) 2014-03-05
RU2007118954A (ru) 2008-11-27
EA012162B1 (ru) 2009-08-28
WO2006047340A2 (en) 2006-05-04
IL182626A0 (en) 2007-07-24
SG156672A1 (en) 2009-11-26
JP5553963B2 (ja) 2014-07-23
MX2007004437A (es) 2007-06-20
JP2008520190A (ja) 2008-06-19
MA29027B1 (fr) 2007-11-01
EP1805320B1 (en) 2014-09-03
EA200700917A1 (ru) 2007-10-26
JP2013055961A (ja) 2013-03-28
EP1805320A2 (en) 2007-07-11
US7928205B2 (en) 2011-04-19

Similar Documents

Publication Publication Date Title
BRPI0517457A (pt) métodos para reenovelamento de anticorpos recombinantes
WO2009036209A3 (en) Homogeneous antibody populations
ATE517909T1 (de) Effizientes gewinnungsverfahren von korrekterweise rückgefalteten proteinen
DE60329489D1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
BR0207067A (pt) Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
DE60115405D1 (de) Verbesserungen in bezug auf ribosom-komplexe als selektionspartikel
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
DE60310562D1 (de) Verfahren zur verstärkung einer immunantwort von nukleinsäureimpfungen
DE602005026931D1 (de) Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
WO2007109742A3 (en) Methods for humanizing antibodies and humanized antibodies made thereby
ATE427963T1 (de) Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von fur antigene niedriger immunogenizitat spezifischen monoklonalen antikírpern
WO2007130535A3 (en) Novel protein fusion/tag technology
ATE366746T1 (de) Gegen das semp1-protein gerichtete antikörper, verfahren zu deren herstellung, und deren anwendungen
DE60228603D1 (de) Antigene und vektoren für impfung
WO2002097041A3 (en) Fusion proteins of biologically active peptides and antibodies
DE60214127D1 (de) Hybridomzelllinie g250 und deren verwendung zur herstellung monoklonaler antikörper
AU2005292852A8 (en) Method of immunizing animal, composition for immunization, method of producing antibody, method of producing hybridoma and method of producing monoclonal antibody
WO2003020005A3 (en) Lp mammalian proteins; related reagents
ATE445017T1 (de) Methode zur herstellung eines polypeptides, einer rna oder einer anderen verbindung in tumorgewebe
MY145649A (en) Methods for refolding of recombinant antibodies
WO2002074906A3 (en) Lp mammalian proteins; related reagents
DE60232155D1 (de) Humaner rekombinanter antikörper gegen das hepatitis c (hcv) nichtstrukturelles ns3 protein, nukleinsäure und deren verwendungen
WO2005058362A3 (en) Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules
WO2002059345A3 (en) Nucleic acid encoding ion transporter component protein

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.